Biosimilar evaluation in Korea

By JinHee Kang, senior regulatory expert, biosimilars more »

Jul 7, 2014 Regulatory Affairs Blog

Waiting game

As we waited to see whether or not Pfizer would be successful in its takeover of AstraZeneca, the approach has raised several issues for the pharmaceutical sector, says Lu Rahman. more »

Jul 7, 2014 Editor's Blog

Future medicines need new thinking, says RPS

Joint effort: Scientists say a new covenant should be developed between the pharma industry and society more »

Jul 7, 2014 Guest Blogs

Applying benchtop NMR spectroscopy in the pharma lab

The latest analytical technology to move to the benchtop is nuclear magnetic resonance (NMR) spectroscopy. High-end, high-cost instrumentation has dominated the NMR sector for many years, with both the initial purchase price and annual running... more »

May 15, 2014 Guest Blogs

Handling pharma recalls — a test of strength for the customer-brand relationship

Pharmaceutical products and medical devices are among the most highly regulated and most thoroughly tested products in the world. In the UK, the MHRA (Medicines and Healthcare Products Regulatory Agency) is responsible for ensuring that all... more »

May 15, 2014 Guest Blogs

Built with Metro Publisher™